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Abstract
Background: Eimeria species are parasitic protozoa that cause coccidiosis, an intestinal disease commonly characterised
by malabsorption, diarrhoea and haemorrhage that is particularly important in chickens. Vaccination against chicken
coccidiosis is effective using wild-type or attenuated live parasite lines. The development of protocols to express foreign
proteins in Eimeria species has opened up the possibility of using Eimeria live vaccines to deliver heterologous antigens
and function as multivalent vaccine vectors that could protect chickens against a range of pathogens.
Results: In this study, genetic complementation was used to express immunoprotective virus antigens in Eimeria tenella.
Infectious bursal disease virus (IBDV) causes Gumboro, an immunosuppressive disease that affects productivity and can
interfere with the efficacy of poultry vaccination programmes. Infectious laryngotracheitis virus (ILTV) causes a highly
transmissible respiratory disease for which strong cellular immunity and antibody responses are required for effective
vaccination. Genes encoding the VP2 protein from a very virulent strain of IBDV (vvVP2) and glycoprotein I from ILTV (gI)
were cloned downstream of 5’Et-Actin or 5’Et-TIF promoter regions in plasmids that also contained a mCitrine fluorescent
reporter cassette under control of the 5’Et-MIC1 promoter. The plasmids were introduced by nucleofection into E. tenella
sporozoites, which were then used to infect chickens. Progeny oocysts were sorted by FACS and passaged several times
in vivo until the proportion of fluorescent parasites in each transgenic population reached ~20 % and the number of
transgene copies per parasite genome decreased to < 10. All populations were found to transcribe and express the
transgene and induced the generation of low titre, transgene-specific antibodies when used to immunise chickens.
Conclusions: E. tenella can express antigens of other poultry pathogens that are successfully recognised by the chicken
immune system. Nonetheless, further work has to be done in order to improve the levels of expression for its future use
as a multivalent vaccine vector.
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Background
The poultry industry provides the principal source of
animal protein in many developed and developing coun-
tries [1]. The adaptability of poultry production systems
has fuelled expansion of the industry to most areas of
the world with high productivity and relatively low costs.
However, intensive systems and backyard flocks remain
threatened by viral, bacterial and parasitic infections that
compromise the economics of meat and egg production,
cause animal welfare problems [2] and can be a signifi-
cant source of zoonotic transmission to humans [3, 4].
Control of infectious diseases that challenge poultry pro-
duction is critical [5] and chickens are more intensively
vaccinated than any other livestock animals. In Europe,
programmes include a minimum of four vaccinations for
broilers whilst layers and breeders can receive up to 20
vaccinations, many to immunise against common viral
diseases including Marek’s disease, Newcastle disease,
Gumboro (infectious bursal disease), infectious bron-
chitis and infectious laryngotracheitis [6].
Coccidiosis is a disease caused by Eimeria species
parasites. In chickens infection can incur a range of
clinical symptoms including malabsorption, diarrhoea
and haemorrhage. The parasites are transmitted by the
faecal-oral route [7]. Coccidiosis control is predomin-
antly achieved by chemoprophylaxis with ionophorous
antibiotics and/or chemical anticoccidials. Vaccination
with formulations of live wild-type or attenuated para-
sites is widely used, and very effective, in layers and
breeders and with an increased role in the broiler mar-
ket due to new regulations (e.g. Veterinary Feed Direct-
ive in the US) and a preference of retailers to sell meat
without antibiotics or with reduced antibiotics. [8]. Pro-
tocols which allow genetic complementation of Eimeria
to express heterologous protein-coding sequences [9]
raises the interesting possibility that existing Eimeria
vaccines could be engineered to express antigens de-
rived from a wide range of poultry pathogens [10, 11].
Eimeria genomes are much larger than those of viral
vectors, in consequence they can tolerate the insertion
and expression of several foreign antigens. They induce
a broad range of potent immune responses following
oral administration [12] having the potential to be
exploited as a flexible oral vaccine vector for intracellu-
lar and extracellular pathogens.
In this study we have expressed in Eimeria tenella spe-
cific antigens that have already been proven capable of
inducing protection against two economically important
viral diseases of chickens. Infectious bursal disease virus
(IBDV) is a birnavirus that causes Gumboro, an acute
and highly contagious disease that destroys B lympho-
cytes within the bursa of Fabricius, causing morbidity,
mortality and immunosuppression, leaving birds suscep-
tible to other infections and compromising vaccination
programmes [13]. The IBDV major capsid protein VP2
is the target of antiviral neutralising antibodies [14–16]
and is already used in a licenced HVT-vectored vaccine
(Vaxxitec, Merial). Infectious laryngotracheitis virus (ILTV)
is an alphaherpesvirus that causes highly contagious acute
respiratory disease leading to growth depression, reduced
egg production and death [17]. A fowlpox virus-vectored
vaccine that expresses ILTV membrane glycoprotein B
(gB) and DNA packaging protein UL-32 is available (Ceva
Bioimmune Vectormune® FP-LT). Additionally, the ILTV
membrane glycoproteins gD and gI have been expressed in
the HVT-vectored vaccine Innovax®-ILT (MSD Animal
Heath).
Therefore, VP2 from a very virulent strain of IBDV
(termed vvVP2) and gI from ILTV were each expressed
in populations of transgenic E. tenella parasites under
the control of E. tenella promoter sequences 5’Et-Actin
[9] or 5’Et-TIF (a genomic region upstream of gene
ETH_00025365 encoding a putative translation initiation
factor, E. Pegg, unpublished) in order to test the suit-
ability of the parasite as an oral vaccine vehicle. The
different transgenic populations were used to immunise
chickens and their ability to develop any type of im-
mune response was analysed.
Methods
Parasites and birds
The E. tenella Wisconsin strain was used throughout
[18]. Oocyst purification, excystation and sporozoite puri-
fication were performed as described previously [19, 20].
Parasites were propagated in 3 week-old White Leghorn
chickens reared under specific pathogen free conditions
and dosed with 4 × 103 sporulated oocysts (by oral intub-
ation), or with 0.75 × 106 transfected sporozoites (by clo-
acal drinking [9]). Transfected sporozoites were also used
to infect monolayers of Madin-Darby bovine kidney
(MDBK; ECACC-Sigma-Aldrich, Salisbury, UK) cells as
previously described [21].
Polymerase Chain Reaction (PCR) and molecular cloning
PCR amplification was performed using Taq DNA Poly-
merase (Invitrogen, California, USA). Primers were de-
signed using CLC Main Workbench software (CLC bio,
Aarhus, Denmark) and synthesised by Sigma. Each PCR
reaction contained DNA template, forward and reverse
primers (20 pmol), Taq polymerase (0.5 U), dNTPs
(0.2 mM; Promega, Hampshire, UK), Tris-HCl (20 mM),
KCl (50 mM) and MgCl2 (2 mM). Standard cycle parame-
ters were 1 × (5 min at 95 oC), 30 × (30 s at 94 oC, 30 s at
56 oC and 1 min at 72 oC) and 1 × (10 min at 72 oC).
Post-amplification PCR products were resolved by agarose
gel electrophoresis, excised and purified using MinElute
Gel Extraction (Qiagen, West Sussex, UK) and cloned into
pGEM®-T Easy (Promega). Plasmids were propagated in
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Escherichia coli XL1-Blue (Stratagene, California, USA),
purified using QIAprep Spin Miniprep (Qiagen) and se-
quenced (GATC Biotech, Konstanz, Germany) as de-
scribed by the respective manufacturers. Sequence
analysis was done using CLC Main Workbench.
Plasmid constructs for transgene expression in E. tenella
Starting plasmid pCIT_CjaA [10] contained the mCitrine
coding sequence directly downstream of the 5’Et-Mic1
promoter, and a second expression cassette where the
viral genes of interest could be cloned downstream of ei-
ther the 5’Et-Actin or 5’Et-TIF promoter region (Fig. 1).
To generate plasmids using the 5’Et-Actin promoter
(Table 1, Fig. 1a), primers incorporating Xho I (for
vvVP2 and gI) or Xba I (for mCherry) and Bgl II restric-
tion sites (Additional file 1: Table S1) were used to amp-
lify the coding sequences of IBDV vvVP2 (accession
number HG974565.1; derived from F52/70 Faragher
challenge virus, GDV-232/270890) and ILTV gI (accession
number KP677883.1; derived from Innovax-ILT vaccine,
HVT-138), combined in the plasmid pVEC211 (kindly
provided by MSD Animal Health) and mCherry fluores-
cent reporter (from Core Construct 1; [9]). The PCR prod-
ucts were cloned into pGEM®-T Easy (Promega) and
digested with Xho I or Xba I and Bgl II (NEB, Hertford-
shire, UK) for subsequent ligation into the pCIT_CjaA
backbone, digested in parallel using the same endonucle-
ases. For the second set of plasmids (Table 1, Fig. 1b),
the 5’Et-Actin promoter sequence was replaced by the
ETH_00025365 (putative translation initiation factor -
TIF) promoter region, 5’Et-TIF. A region of ~1 kb up-
stream of the ETH_00025365 coding sequence was
amplified using primers including Cla I (for vvVP2) or
Bam HI (for gI and mCherry) and Xba I restriction sites
(Additional file 1: Table S1). The PCR products were
cloned into pGEM®-T Easy (Promega) and digested by
Cla I or Bam HI and Xba I (NEB) for subsequent
ligation into the corresponding plasmid. The correct
sequence and insertions for each amplified product
were confirmed by sequencing (GATC Biotech). Final
plasmid DNAs were amplified in E. coli XL1-Blue
(Stratagene), purified using an EndoFree Plasmid Maxi
kit (Qiagen), linearized by digestion with Psi I (0.5 U
per 1 μg of plasmid DNA, NEB, confirmed by running
out in an 0.8 % agarose gel), precipitated in ethanol-
sodium acetate and quantified by NanoDrop (Thermo,
Massachusetts, USA) as recommended by the respect-
ive manufacturers.
Transfection of E. tenella sporozoites
Transfection of purified sporozoites was carried out in
16-well strips using programme EO114 of a Nucleofec-
tor 4D (Lonza, Basel, Switzerland). Restriction enzyme-
mediated integration (REMI) was applied to increase
transfection efficiency [9, 22]. For transfection, four wells
were used, each containing 1 × 106 sporozoites in 20 μl
P3 buffer (Lonza), 12 μg of plasmid DNA (in 2 μl) and 6
U Psi I. Each well was then shocked and 80 μl of RPMI
medium (Sigma, Suffolk, UK) was added per well and in-
cubated at room temperature for 20 min. Transfected
sporozoites from the four wells were combined and used
to infect MDBK cell cultures and/or to infect chickens.
Sporozoite survival rates were estimated after transfec-
tion using Trypan blue dye exclusion (Invitrogen). One
million of the initial transfected sporozoites were incubated
with MDBK cells at 41 °C - 5 % CO2 in 24 well plates,
washed with Advanced DMEM (Gibco, Leicestershire, UK)
(supplemented with 2 % of foetal bovine serum (FBS;
Sigma) and 100 U of Penicillin/Streptomycin (Fisher,
Leicestershire, UK)) after 2 h, and after 24 h the presence
of parasites expressing mCitrine and/or mCherry was con-
firmed by fluorescent microscopy (Leica DMI3000B -
DCF365FX, Wetzlar, Germany).
Obtaining populations of transgenic oocysts
Chickens were infected with transfected sporozoites
equivalent to 0.75 × 106 of the starting sporozoite sample
by direct cloacal inoculation [9]. The precise live sporo-
zoite dose was calculated subsequently based upon sur-
vival during transfection. After 1 week, oocysts were
harvested from caecal contents and sporulated by incu-
bation and agitation in potassium dichromate (2 % w/v)
for 3 days at 27 °C. The proportion of fluorescent para-
sites in each oocyst population was determined by
microscope counts (Leica DMI3000B – DCF365FX) and
fluorescence-activated cell sorting (FACS) on a BD FACS
AriaTM III (BD, California, USA). Further passages of
fluorescent-sorted sporulated oocysts through chickens
were carried out to increase the proportion of transgenic
parasites within the population.
Flow-activated cell sorting (FACS) of transgenic populations
Expression of mCitrine was used to identify parasites
that were successfully transfected with test plasmids.
Fluorescent oocysts were sorted in the BD FACS Aria™
III (BD) using an excitation wavelength of 488 nm, emis-
sion filter of 330/30, a 100 micron nozzle and pressure
of 20 psi. Sample purity (fluorescent events/total events)
was recorded for each population before and after
sorting.
Nucleic acid and protein isolation and complementary
DNA synthesis
TRIzol® Regent (Invitrogen) was used for simultaneous
isolation of RNA, genomic DNA (gDNA) and protein
from oocysts. Two million sporulated oocysts were used
and extractions were performed following the manufac-
turer’s recommendations. RNA and protein pellets were
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stored at -80 °C, gDNA at -20 °C, until further use.
Complementary DNA (cDNA) was synthesized from total
RNA using SuperScript II® reverse transcriptase (200 U;
Invitrogen), random hexamer primers (2.5 μM; Applied
Biosystems, Leicestershire, UK) and RNaseOUT™ recom-
binant ribonuclease inhibitor (40U; Invitrogen) according
to the manufacturer’s instructions. cDNA was stored
at -20 °C until further use. To confirm the absence of
gDNA in the cDNA samples, primers for the Et-Actin
gene were designed across an intron (Additional file 1:
Table S1) such that gDNA contamination of cDNA
would result in amplification of two fragments. The
presence of transgene and transgene transcription was
analysed for each oocyst population by PCR of gDNA
and cDNA samples with specific primers (Additional file 1:
Table S1).
b
p5TIF-vvVP2/gI/mCHE
a
p5Act-vvVP2/gI/mCHE
Fig. 1 Transfection constructs used for the genetic complementation of E. tenella with the viral genes vvVP2 (IBDV), gI (ILTV) or the reporter gene
mCherry under the control of a the 5’Et-Actin promoter region or b the 5’Et-TIF promoter region. The positions of restriction sites used for cloning the
gene or promoter region are indicated for each plasmid
Marugan-Hernandez et al. Parasites & Vectors  (2016) 9:463 Page 4 of 14
Real time quantitative PCR
Real time quantitative PCR (qPCR) was performed in a
CFX96 Touch® Real-Time PCR Detection System (Bio-Rad,
Hertfordshire, UK) using DNA-binding dye SsoFastTM
EvaGreen® Supermix (Bio-Rad). The PCR mixture con-
tained 1 μl DNA template (gDNA or cDNA), SsoFast
EvaGreen supermix (10 μl), forward and reverse primers
(250 nM) and RNase/DNase-free water in a final volume
of 20 μl. Amplification was performed according to the
manufacturer’s protocol, with one cycle at 95 °C for
1 min, followed by 40 cycles at 95 °C for 15 s and 60 °C
for 30 s. All samples were processed in triplicate, supple-
mented by a positive control dilution series and a no
template negative control. Data were analysed with the
Bio-Rad CFX Manager software (Bio-Rad).
The average copy number of transgenes per parasite
genome was determined for each oocyst population using
gDNA and specific primers for mCitrine (to estimate the
transgene copy number) and Eimeria spp. 5S rDNA (to
estimate the total number of genomes) (Additional file 1:
Table S1); as described previously [9].
Transgene transcription was quantified from cDNA
using specific primers (Additional file 1: Table S1) and
compared with serial dilutions of DNA standard tem-
plates for each transgene. pGEM®-T Easy (Promega)
plasmids containing the vvVP2, gI or mCitrine coding
sequences were used as the DNA standard templates.
Standard curves were prepared for all genes from 108 to
102 plasmid copies, against which transcript copy num-
bers were quantified. Data were analysed using the
Kruskal-Wallis test followed by Mann-Whitney test for
pairwise comparison (GraphPad Prism 6 v.6.00, California,
USA).
Expression of rec-vvVP2, rec-gI and rec-gD recombinant
proteins
Sequences corresponding to immunogenic regions (pre-
dicted by CLC Main Workbench software; CLC bio) of
IBDV vvVP2 (nt199-nt657; accession number HG974565.1)
and ILTV gI (nt420-nt810; KP677883.1) and ILTV gD
(nt645-nt1182; KP677882.1) were amplified and cloned into
plasmid vector pET32b (+) (Novagen, Hertfordshire, UK).
DNA fragments were amplified from plasmid pVEC211
(kindly provided from MSD Animal Health) incorporating
Hind III and Xho I restriction sites using the primers listed
in Additional file 1: Table S1. PCR products were sub-
cloned into pGEM®-T Easy (Promega) and digested by
Hind III and Xho I (NEB) for ligation into pET32b(+),
digested in parallel using the same endonucleases.
Recombinant proteins were expressed as polyhistidine
(His6) and thioredoxin fusions in BL21 (DE3) pLysS E.
coli (Stratagene). Bacteria were lysed overnight with
phosphate buffer, 40 mM imidazole, 5 % (v/v) glycerol,
0.5 % (v/v) triton x 100, lysozyme (5KU/gr; Novagen)
and benzonase (25U/ml; Sigma). Insoluble recombinant
proteins (rec-vvVP2 and rec-gI) were denatured in phos-
phate buffer containing 8 M urea and 40 mM imidazole.
Recombinant proteins were purified by immobilized metal
ion affinity chromatography (IMAC) using HisTrap™ HP
columns following the manufacturers protocols (GE Health-
care, Buckinghamshire, UK). After elution in 500 mM imid-
azole, recombinant proteins were checked by SDS-PAGE
(Invitrogen) and protein concentration estimated by Brad-
ford assay (Invitrogen) using serial dilutions of bovine serum
albumin (BSA) as standard.
Immunogenicity trial
To evaluate the potential of E. tenella transgenic oocyst
populations to stimulate specific antibody responses
against an expressed transgene, groups of 21-day-old
White Leghorn chickens were immunised orally with
oocysts containing IBDV vvVP2 or ILTV gI transgenes
under the control of either the 5’Et-Actin or 5’Et-TIF
promoter. Birds dosed with E. tenella wild type oocysts
or with PBS were used as controls (Table 2). To mimic
the re-cycling of parasites that occurs in natural infections,
chickens were infected on more than one occasion, as
stated in Table 2. Faeces were collected from each group
of birds at 3 and 7 days after the first infection and oocysts
were recovered to demonstrate successful inoculation of
birds with transgenic or wild type E. tenella. Data were
analysed by Chi-square test followed by Fisher’s exact test
(GraphPad Prism 6 v.6.00).
All birds were cardiac bled under terminal anaesthesia
at the end of the study at 57 days of age (42 days after
the last immunisation). Bloods were incubated at 37 °C
for 2 h, then transferred to 4 °C overnight and serum
collected after centrifugation at 10,000 g for 10 min and
stored at -20 °C until further use.
SDS-polyacrylamide gel electrophoresis (PAGE), Western
blot and ELISA
Total protein extracted by TRIzol® Reagent (Invitrogen)
from passaged oocysts of transgenic or wild type para-
sites was electrophoresed through NuPAGE 4–12 %
Table 1 Summary of plasmid constructs used for genetic
complementation of E. tenella
Plasmid Fluorescent reporter Target gene Gene promoter
p5Act-vvVP2a 5’EtMic1-mCitrine-3’EtMic1 vvVP2 (IBDV) 5’Et-Act
p5Act-gIa 5’EtMic1-mCitrine-3’EtMic1 gI (ILTV) 5’Et-Act
p5Act-mCheb 5’EtMic1-mCitrine-3’EtMic1 mCherry 5’Et-Act
p5TIF-vvVP2a 5’EtMic1-mCitrine-3’EtMic1 vvVP2 (IBDV) 5’Et-TIF
p5TIF-gIa 5’EtMic1-mCitrine-3’EtMic1 gI (ILTV) 5’Et-TIF
p5TIF-mCheb 5’EtMic1-mCitrine-3’EtMic1 mCherry 5’Et-TIF
aUsed for the generation of stable populations
bUsed to test mCherry expression in transient transfection
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Bis-Tris 10 well gels (Invitrogen) in Laemmli loading
buffer (Sigma). Proteins were transferred to nitrocellu-
lose membranes (GE Healthcare) in a semidry system
following the manufacturers protocols (Invitrogen) and
blocked in 5 % (w/v) blotting grade non-fat milk (Bio-
Rad) overnight. Membranes were incubated for 1 hour
with a 1/100 dilution of a set of sera kindly provided by
MSD Animal Health: anti-mouse MCA-LTV-Mab6-
INT and anti-chicken ILT Spafas for gI; anti-mouse
MCA 10-INT and anti-mouse IBDV R63 MoAb for
vvVP2. After washing three times with TBS-Tween
0.05 % (v/v) membranes were incubated for 1 hour with
goat anti-mouse IgG antibody horseradish peroxidase
(HRP) conjugate (Merk Millipore, Hertfordshire, UK)
or rabbit anti-chicken IgG antibody HRP conjugate
(Merk Millipore). Membranes were washed three times
with TBS-Tween 0.05 % (v/v), once with TBS and finally
with distilled water before adding Luminata substrate
(Merck Millipore). Chemiluminiscence was visualised
in a G:BOX (Syngene, Cambridge, UK) and images
were taken with GeneSnap 7.12 software (Syngene).
To determine whether immunised chickens developed
specific antibodies against vvVP2, gI or E. tenella, 5 μg
of rec-vvVP2 or rec-gI recombinant proteins or 107 E.
tenella sporozoites were electrophoresed through
NuPAGE 4–12 % Bis-Tris 1 well gels (Invitrogen) in
Laemmli loading buffer (Sigma). Proteins were trans-
ferred and blocked as described above. The membranes
were incubated with different dilutions of chicken serum
(1/200 - 1/100 - 1/50) and corresponding controls (sera
from chickens immunised with Vaxxitec for vvVP2 and
with ILT Spafas for gI) in a multiscreen apparatus (Bio-
Rad) for 1 hour, washed three times with TBS-Tween
0.05 % (v/v) and incubated again for 1 hour with rabbit
anti-chicken IgG antibody HRP conjugate (Merck Milli-
pore). Membranes were washed and developed as de-
scribed above. Antisera were also analysed by enzyme-
linked immunosorbent assay (ELISA) at The Service La-
boratory (Boxmeer, Netherlands) using an IDEXX IBD
Antibody Test Kit for vvVP2 and the ProFLOK® ITL
Antibody Test Kit. The presence of neutralising anti-
bodies for vvVP2 were also analysed using the GDV D78
VN assay.
Lymphoproliferation assays
An experiment replicating the immunization schedule of
the immunogenicity assay (as above and Table 2) using
7-day-old chickens, was performed to analyse the ability
of vvVP2 and gI antigens, expressed by E. tenella, to in-
duce lymphocyte proliferation. In this experiment groups
of four chickens were used. For peripheral blood mono-
nuclear cells (PBMC), birds were bled from the wing vein
at 7 and 14 days after the last immunization; blood was
treated with heparin to avoid coagulation (0.3 U/ μl) and
1 ml was mixed with Histopaque 1077 (Sigma) (1:1). For
splenocytes, spleens were removed at post-mortem
(21 days after the last immunization), sliced, washed with
PBS, passed through a cell strainer (40 μm) and the hom-
ogenate (6 ml) was mixed with Histopaque 1077 (Sigma)
(1:1). Samples were centrifuged at 1250 g for 30 min and
the interphase recovered and washed with 1 ml (PBMC)
or 5 ml (splenocytes) of PBS three times (600 g – 15 min),
then resuspended in 1 ml or 5 ml RPMI containing 10 %
(v/v) FBS. Isolated cells were counted and 105 cells added
per well in 96-well-plates, using 12 wells per group.
PBMC and splenocytes were stimulated with Conca-
navalin A (ConA; 5 μg/ml; Sigma), soluble E. tenella
antigen (10 μg/ml), recombinant protein (vvVP2 or gI;
10 μg/ml) or PBS and incubated at 41 °C with 5 % CO2
for 5 days. Cell proliferation was monitored by the incorp-
oration of tritiated thymidine (3H-Tdr, specific activity
485 GBq/mmol; Thermo), 37 kBq 3H-Tdr were added
for the final 24 h of incubation. Plates were then stored
at -20 °C for at least 1 day and cells were harvested
onto with a semi-automated cell harvester (Skatron,
California, USA) and counted in a 1205 Betaplate™
counter (Wallac, Zurich, Switzerland). Data were ana-
lysed by a one-way ANOVA with post-hoc Bonferroni
test (SPSS Statistics 22, New York, USA).
Results
Transiently transfected E. tenella sporozoites expressed
foreign antigens under the regulation of two different
promoter regions
The functionality of promoters 5’Et-Actin and 5’Et-TIF
was confirmed by detection of red fluorescence in sporo-
zoites transfected with constructs containing mCherry
Table 2 Experimental groups used for immunisation trial
Group Parasite population No. of birds 100 oocysts 500 oocysts 3000 oocysts 5000 oocysts
1 Et-Act-vvVP2-P6 12 day 0 day 4 day 6 day 13
2 Et-TIF-vvVP2-P2 12 day 0 day 4 day 6 day 13
3 E. tenella (wt) 6 day 0 day 4 day 6 day 13
4 Et-Act-gI-P5 12 day 0 day 2 day 8 day 14
5 Et-TIF-gI-P2 12 day 0 day 2 day 8 day 14
6 E. tenella (wt) 6 day 0 day 2 day 8 day 14
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cloned downstream of each promoter (Table 1, Fig. 2a).
Quantification of transgene copy number per parasite
genome and the level of transgene transcription was not
carried out in these short-term sporozoite cultures be-
cause non-integrated plasmid was also detected, evi-
denced by a number of mCitrine copies per genome
determined by qPCR to exceed 35,000 (data not shown).
Viral proteins were expressed in transgenic populations
of sporulated oocysts, and transgene copy number per
parasite genome reduced after in vivo parasite passage
Sporozoites transfected with the different plasmids
(Table 1) showed a survival between 17.5 and 24.0 %
and were used to infect chickens and generate oocysts
(Table 3). The populations that emerged contained mix-
tures of fluorescent and non-fluorescent oocysts. Each
population was enriched for fluorescent oocysts after
sporulation by FACS sorting (85–95 % purity) and re-
passaged in chickens on two to six occasions per plas-
mid (Table 3, Fig. 2b). The proportion of fluorescent oo-
cysts increased after passaging, but did not exceed 22 %
in any example (Fig. 3a).
The presence and expression of mCitrine in transgenic
parasites was evidenced by fluorescence (Fig. 2b). The
presence of the second cassette containing each foreign
gene was confirmed by PCR with gene-specific primers
(Additional file 1: Table S1). These same primers were
also used to confirm transgene transcription by real time
PCR (RT-PCR).
Variation in the number of transgene copies per gen-
ome was analysed for each generation of transgenic
parasites. The transgene copy number dropped dramat-
ically after two passages, and thereafter further passages
were done until they stabilised at an average of less than
ten copies per genome (Fig. 3b).
To determine the occurrence of transgene expression
a band of the expected size (~62 kDa) was detected by
Western blotting using extracts of transgenic popula-
tions expressing gI (Et-Act-gI and Et-TIF-gI) when they
were incubated with MCA-LTV-Mab6-INT (Fig. 3c). A
second band of ~56 KDa was also detected in both
transgenic populations but was absent from the wild-
type parasites. Recognition with a second antibody, ILT
Spafas, was not conclusive (Fig. 3c). In contrast no clear
recognition of a protein of the expected size (~42 kDa)
was observed in extracts of transgenic populations express-
ing vvVP2 (Et-Act-vvVP2 and Et-TIF-vvVP2) (Fig. 3c), only
an unspecific band (~59 kDa) which was conserved within
the wild-type sample was observed.
Transcription levels of viral transgenes in sporulated
oocysts were independent of the promoter region used
Each plasmid carried two coding sequences under the
regulation of different promoters, 5’Et-Mic1 linked to
mCitrine and 5’Et-Actin or 5’Et-TIF linked to vvVP2 or
gI. In order to determine the relative level of transcrip-
tion of 5’Et-Actin or 5’Et-TIF in relation to 5’Et-Mic1 a
reverse transcription qPCR was performed. The tran-
scription of mCitrine linked to 5’Et-Mic1 was always
higher than transcription of vvVP2 or gI linked to either
5’Et-Actin or 5’Et’TIF (Table 4). When expressing gI,
5’Et’TIF lead to a stronger transcription than 5’Et-Actin
p5Act-mChe
mCherry mCitrine Sporozoites Merge
p5TIF-mChe
mCitrine Oocysts Merge
Caecal 
harvest
FACS
a
b
Fig. 2 Transgenic parasites expressing fluorescent reporters. a Transiently transfected sporozoites expressing mCherry under the control of 5’Et-Actin
(panel above) or 5’Et-TIF (panel below) and mCitrine under the control of 5’Et-Mic1. Scale-bars: 40 μm. b Oocysts recovered by caecal harvest
following in vivo passage (panel above) and after enrichment by FACS (panel below). Scale-bars: 100 μm
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(an average of 2.1 times more). However, when express-
ing vvVP2, the promoter region 5’Et-Actin led to a
stronger transcription than 5’Et’TIF (an average 9.4
times more).
Immunisation of chickens with transgenic parasites led to
the generation of specific antibodies but did not trigger
lymphocyte proliferation in a re-stimulation assay
The presence of specific antibodies 42 days after the last
immunisation against rec-vvVP2 or rec-gI was tested by
Western blot for all groups of chickens immunised using
the relevant transgenic parasite population, with be-
tween one and eight of twelve birds found to be positive
per group (Fig. 4a). However, the sera were reactive only
at high concentrations (Fig. 4b), none were positive
when tested with commercial ELISA kits and the ELISA
specific for virus neutralising antibodies resulted in a
2Log titre of < 5 (equivalent to a titre of less than 1 in
32; Additional file 1: Table S2). The frequency of anti-
body detection by Western blot was significantly higher
for the group immunised with Et-TIF-gI compared to
that immunised with Et-TIF-vvVP2 (P < 0.05, Fisher’s
exact test), but there were no other significant differences
found between any other groups. All sera from immunised
chickens, whether positive or negative against the recom-
binant proteins, were positive when tested against E.
tenella extracts (Additional file 1: Figure S1).
PBMC from birds immunised with transgenic parasites
expressing vvVP2 (Et-Act-vvVP2 and Et-TIF-vvVP2)
were isolated and re-stimulated in vitro at day 7 and 14
post-immunisation. Proliferation was observed when
they were stimulated with the unspecific stimulator
ConA (data not shown) or with E. tenella soluble anti-
gen only at day 7. However, there were no significant
changes (P > 0.05, one-way ANOVA) when rec-vvVP2
was added to the media compared with the PBS controls
or a non-specific recombinant protein (rec-gD) (Fig. 5).
Birds immunised with transgenic parasites expressing gI
(Et-Act-gI and Et-TIF-gI) were not tested at these time
points. Splenocytes from birds of all immunised groups
were isolated and stimulated at day 21 post-immunisation.
Similar to what was observed for the PBMC, only ConA
(data not shown) and E. tenella soluble antigen were able
to stimulate the cells (Fig. 5).
Discussion
In this study new transgenic populations of E. tenella ex-
pressing antigens from either of two viruses that cause
serious diseases in chickens, IBDV and ILTV, have been
generated. Oral immunisation of chickens using these
parasites was able to induce specific antibody responses
against the viral antigens in some, but not all individuals.
The idea of using Eimeria parasites as multivalent vac-
cine vectors was suggested several years ago, and to date
some partial success has been reported. Clark et al. [10]
expressed Campylobacter jejuni antigen CjaA in E.
tenella and whilst birds immunised with the transgenic
parasites were protected (~90 % reduction in C. jejuni in
the caeca 2 weeks after challenge, compared to controls)
evidence of immunological recognition of the antigen by
the chicken was inconclusive. Moreover, Liu et al. [11]
generated parasites expressing the M2 protein of the
avian influenza virus, but found no evidence of antibody
or cellular responses. The only immune responses re-
ported in chickens raised by transgenic Eimeria has been
against a fluorescent reporter protein (EYFP) [23], there-
fore, this is the first time that antibodies against viral
proteins expressed in transgenic Eimeria have been re-
ported. The antibodies were detected by Western blot-
ting only when sera were used at low dilution and none
were positive in standard commercial ELISA kits, which
use sera at higher dilutions. Nevertheless, these results are
significant since they demonstrate that the viral antigens
were expressed and available to the chicken immune sys-
tem. Improving the consistency of immunisation remains
a major challenge.
The integration and transcription of transgenes, both
for vvVP2 or gI, was shown in all the transgenic popula-
tions and for gI it was possible by Western blotting to
identify proteins of the expected mass within extracts of
sporulated oocysts. Antibodies against gI recognised two
bands in the parasite extract and these could potentially
correspond to unmodified and modified forms. Unmodi-
fied and N-glycosylated forms have been described for
native viral gI [24]. The E. tenella proteome has been
shown to include multiple proteins associated with gly-
cosylation, including N-glycosylation [25], and while the
modifications may not be identical in the two organisms,
post-translational changes may explain the occurrence of
two bands in transgenic, but not wild-type parasites. For
Table 3 Sporozoite survival after transfection, the numbers used to initiate the primary infection and the total number of
generations produced for each plasmid
Transfected plasmid Parasite survival (%) Number of live sporozoites dosed per chicken Number of in vivo passages
p5Act-vvVP2 17.5 131,250 6
p5Act-gI 24.0 180,000 5
p5TIF-vvVP2 21.6 162,080 2
p5TIF-gI 22.4 168,341 2
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vvVP2, we could not directly prove protein expression in
the parasites by Western blot because the antibodies ex-
pected to react with vvVP2 failed to recognise any form
of recombinant vvVP2 cloned and produced in this same
study. We infer vvVP2 expression by indirect methods
including visualisation of mCherry expressed in the same
vector frame, detection of vvVP2 transcripts and the
presence of specific antibodies in immunised chickens.
The high sera concentration necessary for detection of
specific antibodies against vvVP2 or gI, may relate to the
total amount of foreign antigen being exposed to the
chickens immune system. The immunisations in this
study were done following protocols for vaccinations
against Eimeria, in which the maximum number of oo-
cysts inoculated was 5000 in the last immunisation.
These numbers are considerably lower than those used
with other live vectors such as Salmonella Typhimur-
ium, for which doses from 107 to 109 organisms express-
ing VP2 were dosed [26]. Therefore, an interesting
option could be the transference of these transgenic
technologies to more fecund Eimeria species such as
E. acervulina or E. mitis [27] in order to increase the
number of transgene expressing organisms per
immunisation.
Further, the transgenic populations used for the immu-
nisations were unstable with respect to transgene reten-
tion and expression. Chickens were infected with
populations enriched by FACS to contain between 85 %
and 95 % fluorescent oocysts, however the harvested oo-
cyst output collected after each passage always contained
less than 22 % fluorescent oocysts. Some possible rea-
sons for this instability have been discussed previously
by Clark et al. [9], including genetic segregation and re-
combination leading to transgene loss. Working with
stable lines of transgenic parasites which maintain trans-
gene expression after every passage might improve the
efficacy of vaccination, although the difficulties associ-
ated with obtaining clonal lines precludes routine use
during medium throughput testing. Specifically, Eimeria
cannot be cloned in vitro by serial dilution or similar
procedures. Instead, single sporocyst infection of chickens
is needed to clone Eimeria, which is a time-consuming
and inefficient process [11, 28]. Non-clonal populations
that have 100 % transgenic parasites can be obtained by
applying drug selection over several in vivo passages to
parasites where a drug-resistance cassette has been incor-
porated in the transfection process [9]; however, inclusion
of drug-resistant genes is not appropriate for populations
to be administrated as live vaccines in field chicken
populations.
The choice of promoters to control timing and level of
expression of the downstream transgene could be im-
portant for optimising recognition of foreign antigens by
the host immune system. We characterised parasite pop-
ulations expressing vvVP2 or gI using 5’Et-Actin, a con-
stitutive promoter used previously [9, 28] or 5’Et-TIF, a
novel promoter identified from an RNAseq database
[29] that is linked to a gene transcribed ~ 10 fold higher
than Et-Actin. However when transgene transcripts
(vvVP2 or gI) under the control of the two different pro-
moters (5’Et-Actin or 5’Et-TIF) were quantified, in rela-
tion to mCitrine expressed under control of 5’Et-Mic1
on the same plasmid, 5’Et-TIF was found to promote
higher transcription for gI, but not for vvVP2, suggesting
that the downstream transgene could be affecting the
transcription regulation.
Protection against viral infections such as IBDV and
ILTV can be achieved by the induction of a high titre of
neutralising antibodies as demonstrated using the VP2
antigen for IBDV [30, 31], in contrast to more compli-
cated immune mechanisms necessary to provide protec-
tion against other pathogens (eg. Clostridium perfringens
[32]). While we have shown that the Eimeria expression
(See figure on previous page.)
Fig. 3 Analysis of transgenic E. tenella populations. a The percentage fluorescence detected for each transgenic population with successive in
vivo passage. b Number of transgene copies per parasite genome for each transgenic population with successive passage through chickens. The
number of copies was calculated using a standard curve of E. tenella gDNA. c Western blot of the different transgenic populations; Et-Act-gI-P5:
lanes 2, 5; Et-TIF-gI-P2: lanes 3, 6; Et-Act-vvVP2-P6: lanes 8, 11; Et-TIF-vvVP2-P2: lanes 9, 12; and E. tenella (wt): lanes 4, 7, 10, 13; incubated with MCA-LTV-
Mab6-INT (lanes 2–4) or ILT Spafas (lanes 5–7) for gI recognition and MCA 10-INT (lanes 8–10) or IBDV R63 MoAb (lanes 11–13) for vvVP2 recognition. Lane
1 is the Mw. Solid black arrows indicate specific band recognition with a size of ~62 kDa for gI and a processed form of it ~56 kDa (lines 2 and 3). Dotted
white arrows indicate potential band recognition with sizes of ~62 kDa for gI and ~42 kDa for vvVP2 (lines 5, 6 and 8)
Table 4 Relative transcription levels of the foreign gene in
cassette 2 (vvVP2 or gI) compared with mCitrine in cassette 1 in
different transgenic populations
Population mCitrine/vvVP2c Population mCitrine/gIc
Et-Act-vvVP2-P1 34.7a Et-Act-gI-P1 139.0a
Et-Act-vvVP2-P2 4.2a Et-Act-gI -P2 36.3a
Et-Act-vvVP2-P3 4.2a Et-Act-gI -P3 82.6a
Et-Act-vvVP2-P4 6.4a Et-Act-gI -P4 62.8a
Et-Act-vvVP2-P5 1.7a Et-Act-gI -P5 182.8a
Et-Act-vvVP2-P6 0.4a
Et-TIF-vvVP2-P1 67.2b Et-TIF-gI-P1 76.9b
Et-TIF-vvVP2-P2 94.9b Et-TIF-gI-P2 17.4b
aEquivalent to 5’Et-Mic1 / 5’Et-Actin ratio
bEquivalent to 5’Et-Mic1 / 5’Et-TIF ratio
cRatio indicates the times mCitrine is higher than the other transcript
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system can be used to stimulate host immune recogni-
tion of foreign antigens, the levels of humoral response
generated are likely to be insufficient to guarantee pro-
tection against challenge [33]. Prior to conducting an in
vivo challenge the consistency and magnitude of im-
mune response stimulated by transgenic Eimeria vac-
cination should be improved. Options include the use
of promoters capable of inducing stronger transgene
expression, or addition of targeting signals for delivery
to the cell surface or secretion, which could to improve
the exposition of the antigen and therefore its recogni-
tion [23, 34]. Optimization of the number of parasites
per vaccinating dose or transference of the technology
to more fecund Eimeria species might also encourage
stimulation of more significant immune response.
Novel technologies for directed integration such as
CRISPR/Cas9 [35, 36] or the generation of clonal lines
could also offer some advantages, improving accurate
characterization of transgenic parasites and improving
uniformity.
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Fig. 4 Humoral immune responses by chickens immunised with E. tenella transgenic populations and wild type parasites. a Proportion of chickens
presenting a positive reaction against rec-vvVP2 or rec-gI by western blot. * Indicates significant differences between groups in the frequency of
recombinant protein detection (P < 0.05, Fisher’s exact test). b Western blot of chicken sera against rec-vvVP2 (panel above); lanes 1-2: positive sera
from chickens immunised with Et-Act-vvVP2-P6 at dilutions 1/50, 1/100 or 1/200; lanes 3-4: positive and negative sera from chickens immunised with
Et-TIF-vvVP2-P2 at dilutions 1/50, 1/100 or 1/200; lane 5: negative control (sera from chickens immunised with E. tenella (wt) at dilution 1/50); lane 6:
positive control (sera from chickens immunised with Vaxxitec at dilution 1/100) and Western blot of chicken sera against rec-gI (panel below); lanes
1–7: chicken reacting positive (1–3: Et-Act-gI-P5 at dilution 1/50; 4–7: Et-TIF-gI-P2 at dilution 1/50); lanes 8–12: chicken reacting negative (8–9:
Et-Act-gI-P5 at dilution 1/50; 10–12: Et-TIF-gI-P2 at dilution 1/50); lane 13: negative control (sera from chickens immunised with E. tenella (wt)
at dilution 1/50); lane 14: positive control (anti-chicken ILT Spafas at dilution 1/200). Rabbit anti-chicken IgG antibody HRP conjugate (Merk
Millipore) at 1/1000 dilution was used as secondary antibody
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Conclusions
Newly generated transgenic populations of E. tenella are
capable of expressing viral antigens vvVP2 from IBDV
and gI from ILTV. Moreover, these expressed antigens
were recognised by the chicken immune system as evi-
denced by the presence of specific antibodies in the sera,
providing the first report of specific antigen recognition
from viral avian pathogens expressed by transgenic
Eimeria. Nonetheless, the low level response detected
indicates a requirement of improve transgene expression
before testing as a vaccine.
Additional file
Additional file 1: Table S1. Primers used in the study. Table S2.
Analysis of post infection serum. Figure S1. Western blot of total E. tenella
sporozoite extract against chicken sera immunised by infection with different
transgenic or wild-type populations of E. tenella. Lane 1: Et-Act-vvVP2-P6; lane
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Fig. 5 Proliferation of PMBC and splenocytes isolated from chickens immunised with the different transgenic populations (Et-Act-vvVP2, Et-TIF-vvVP2,
Et-Act-gI or Et-TIF-gI) after stimulation with E. tenella soluble antigens, the corresponding recombinant antigen (rec-vvVP2 or rec-gI), an unspecific
antigen (rec-gD) or PBS. *, ** indicate different significances, only E. tenella soluble extract induced linfoproliferation at days 7 (Et-Act-vvVP2:
F(3,46) = 11.825, P < 0.00001; Et-TIF-vvVP2: F(3,45) = 9.041, P < 0.00001; one-way ANOVA) and 21 (Et-Act-vvVP2: F(3,24) = 12.439, P < 0.00001; Et-TIF-
vvVP2: F(3,42) = 9.470, P < 0.00001; Et-Act-gI: F(3,35) = 11.769, P < 0.00001; Et-TIF-gI: F(3,28) = 11.870, P < 0.00001; one-way ANOVA). No significant lin-
foproliferation was observed at day 14 (Et-Act-vvVP2: F(2,10) = 2.557, P = 0.127; Et-TIF-vvVP2: F(2,27) = 1.091, P = 0.350; one-way ANOVA)
Marugan-Hernandez et al. Parasites & Vectors  (2016) 9:463 Page 12 of 14
2: Et-TIF-vvVP2-P2; lane 3: Et-Act-gI -P5; lane 4: Et-TIF-gI-P2; lane 5: E. tenella (wt);
lanes 6–7: non-immunised; lane 8: positive control (anti-EtMic2); lane 9:
Coomassie blue of E. tenella sporozoite extract; lane 10: Mw. Rabbit
anti-chicken IgG antibody HRP conjugate or goat anti-mouse IgG antibody
HRP (for EtMic2) conjugate at 1/1000 dilution were used as secondary
antibody. (DOCX 3094 kb)
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